A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)

Kenrick Ng(University College Hospital), Jonathan Shamash(Queen Mary University of London), Shah‐Jalal Sarker(Queen Mary University of London), Angus Robinson(Royal Sussex County Hospital), Norman Taylor(King's College Hospital NHS Foundation Trust), Michelle Greenwood(St Bartholomew's Hospital), Ernese Xhafa‐Hamiti(St Bartholomew's Hospital), Garima Priyadarshini(Queen Mary University of London), William Drake, Neil McPhail(Cancer Research UK), Aaron Prendergrast(Queen Mary University of London), Charlotte Ackerman(Queen Mary University of London)
The Prostate
March 18, 2025
10.1002/pros.24877
Cited by 0

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
|Cancer Cell|2018|591
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374